355 related articles for article (PubMed ID: 9480140)
1. [Shortening of acetylsalicylic acid-prolonged bleeding time by means of desmopressin].
Beck KH; Bleckmann U; Mohr P; Kretschmer V; Huss B
Beitr Infusionsther Transfusionsmed; 1994; 32():437-9. PubMed ID: 9480140
[TBL] [Abstract][Full Text] [Related]
2. DDAVP's shortening of the bleeding time seems due to plasma von Willebrand factor.
Beck KH; Bleckmann U; Mohr P; Kretschmer V
Semin Thromb Hemost; 1995; 21 Suppl 2():40-3. PubMed ID: 7660156
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo effects of desmopressin on platelet function.
Balduini CL; Noris P; Belletti S; Spedini P; Gamba G
Haematologica; 1999 Oct; 84(10):891-6. PubMed ID: 10509036
[TBL] [Abstract][Full Text] [Related]
4. Platelet aggregation at high shear is impaired in patients with congenital defects of platelet secretion and is corrected by DDAVP: correlation with the bleeding time.
Cattaneo M; Pareti FI; Zighetti M; Lecchi A; Lombardi R; Mannucci PM
J Lab Clin Med; 1995 Apr; 125(4):540-7. PubMed ID: 7706911
[TBL] [Abstract][Full Text] [Related]
5. Uremic plasma after infusion of desmopressin (DDAVP) improves the interaction of normal platelets with vessel subendothelium.
Escolar G; Cases A; Monteagudo J; Garrido M; Lopez J; Ordinas A; Revert L; Castillo R
J Lab Clin Med; 1989 Jul; 114(1):36-42. PubMed ID: 2738447
[TBL] [Abstract][Full Text] [Related]
6. Desmopressin effect on acetylsalicylic acid impaired platelet function.
Beck KH; Mohr P; Bleckmann U; Schweer H; Kretschmer V
Semin Thromb Hemost; 1995; 21 Suppl 2():32-9. PubMed ID: 7660155
[TBL] [Abstract][Full Text] [Related]
7. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of platelet dysfunction and response to DDAVP in patients with congenital platelet function defects. A double-blind placebo-controlled trial.
Rao AK; Ghosh S; Sun L; Yang X; Disa J; Pickens P; Polansky M
Thromb Haemost; 1995 Oct; 74(4):1071-8. PubMed ID: 8560416
[TBL] [Abstract][Full Text] [Related]
9. [Utility of desmopressin in 4 cases of thrombocytopathies associated with giant platelets].
Martínez-Murillo C; Quintana-González S; Ambriz-Fernández R; Arzate-Hernández G; Gutiérrez-Romero M; Gaminio-Gómez E
Rev Invest Clin; 1997; 49(4):281-6. PubMed ID: 9707993
[TBL] [Abstract][Full Text] [Related]
10. Laboratory response to intranasal desmopressin in women with menorrhagia and platelet dysfunction.
Rose SS; Faiz A; Miller CH; Saidi P; Philipp CS
Haemophilia; 2008 May; 14(3):571-8. PubMed ID: 18312366
[TBL] [Abstract][Full Text] [Related]
11. Retention test Homburg to monitor the adhesive properties of von Willebrand factor after substitution or desmopressin therapy.
Wieding JU; Matern J; Köstering H; Wermes C; Wenzel E
Semin Thromb Hemost; 2005; 31(4):441-8. PubMed ID: 16149022
[TBL] [Abstract][Full Text] [Related]
12. Shortening of bleeding time by 1-deamino-8-arginine vasopressin (DDAVP) in the absence of platelet von Willebrand factor in Gray platelet syndrome.
Pfueller SL; Howard MA; White JG; Menon C; Berry EW
Thromb Haemost; 1987 Dec; 58(4):1060-3. PubMed ID: 3502198
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of desmopressin effect on primary haemostasis in pediatric patients with aspirin-like defect as hereditary thrombocytopathy.
Tauer JT; Gneuss A; Lohse JE; Jürgens T; Knöfler R
Klin Padiatr; 2011 May; 223(3):169-72. PubMed ID: 21509710
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the buccal bleeding time and platelet glass bead retention as assays of hemostasis in the dog: the effects of acetylsalicylic acid, warfarin and von Willebrand factor deficiency.
Brassard JA; Meyers KM
Thromb Haemost; 1991 Feb; 65(2):191-5. PubMed ID: 2053106
[TBL] [Abstract][Full Text] [Related]
15. Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry.
Giannini S; Mezzasoma AM; Leone M; Gresele P
Haematologica; 2007 Dec; 92(12):1647-54. PubMed ID: 18055988
[TBL] [Abstract][Full Text] [Related]
16. The von Willebrand factor antagonist (GPG-290) prevents coronary thrombosis without prolongation of bleeding time.
Wadanoli M; Sako D; Shaw GD; Schaub RG; Wang Q; Tchernychev B; Xu J; Porter TJ; Huang Q
Thromb Haemost; 2007 Aug; 98(2):397-405. PubMed ID: 17721623
[TBL] [Abstract][Full Text] [Related]
17. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
18. [Effect of desmopressin (DDAVP) on blood platelet parameters in vivo and in vitro].
Kätzel R; Dietzel H; Selle B; Taube C
Z Gesamte Inn Med; 1992 Jul; 47(7):303-7. PubMed ID: 1496839
[TBL] [Abstract][Full Text] [Related]
19. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA.
McCabe DJ; Harrison P; Mackie IJ; Sidhu PS; Lawrie AS; Purdy G; Machin SJ; Brown MM
Platelets; 2005 Aug; 16(5):269-80. PubMed ID: 16011977
[TBL] [Abstract][Full Text] [Related]
20. Platelet hyporesponsiveness to acetylsalicylic acid can be transferred by plasma in humans.
Anger K; Kempfert J; Kostelka M; Mohr FW; Dhein S
Pharmacology; 2010; 85(4):241-7. PubMed ID: 20332671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
